On the stock market since 1980, it operates in the world of health and science. It has 125,000 employees. Now — the numbers.
This is an established company with proven profits.
The gap is $30.7B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 22% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 15% — still a thick cushion, though costs have been eating into it lately.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
It pays out $1.80 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales fell about 0% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 23/100.
The growth engine is running at low revs right now. Report-card grade: 44/100.
On our five-subject report card, TMO sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: TMO is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.